Evidence map›Paper›PMID 29032174›Full record

ArticleBone2018

C/EBPα and PU.1 exhibit different responses to RANK signaling for osteoclastogenesis.

Joel Jules, Yi-Ping Li, Wei Chen

Open access · greenAbstract read
In one paragraph

Article in Bone, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Role and Regulation of Transcription Factors in Osteoclastogenesis.International journal of molecular sciences · 2023
    Review
  3. LncRNA-Mediated Adipogenesis in Different Adipocytes.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Joel JulesDepartment of Pathology, University of Alabama, Birmingham, AL 35294, United States.
Yi-Ping LiDepartment of Pathology, University of Alabama, Birmingham, AL 35294, United States. Electronic address: yipingli@uabmc.edu.
Wei ChenDepartment of Pathology, University of Alabama, Birmingham, AL 35294, United States. Electronic address: weichen@uabmc.edu.
University of Alabama at Birmingham · US

Funding

TRANSCRIPTION FACTORS CONTROL OSTEOCLAST DIFFERENTIATIONR01AR044741 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, YI-PING · 1999 to 2016
$5.1M
Inhibiting Periodontitis by Targeting Cathepsin K and Attenuating TLR SignalingR01DE023813 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, YI-PING · 2014 to 2023
$3.9M
Cbfβ mediates articular cartilage regeneration and repair in agingR01AG056438 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHEN, WEI · 2019 to 2023
$2.1M
Characterizing the mechanism by which endogenous negative regulators of osteoclasts control bone homeostasis under physiological and pathological conditions in mouse modelsR01AR070135 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHEN, WEI · 2017 to 2021
$1.6M
Cbfβ mediates articular cartilage regeneration and repair in agingR56AG056438 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHEN, WEI · 2017 to 2017
$371k
NIAMS NIH HHS R01 AR044741NIAMS NIH HHS R01 AR070135NIA NIH HHS R01 AG056438NIA NIH HHS R56 AG056438NIDCR NIH HHS R01 DE023813
6 · The paper itself

Abstract

The transcription factors C/EBPα and PU.1 are upregulated by RANKL through activation of its receptor RANK during osteoclastogenesis and are critical for osteoclast differentiation. Herein we investigated the mechanisms underlying how C/EBPα and PU.1 regulate osteoclast differentiation in response to RANK signaling. We showed that C/EBPα or PU.1 overexpression could initiate osteoclastogenesis and upregulate the expressions of the osteoclast genes encoding the nuclear factor of activated T-cells, C1, cathepsin K, and tartrate-resistant acid phosphatase independently of RANKL. However, while PU.1 upregulated C/EBPα, C/EBPα could not upregulate PU.1. RANK has a unique cytoplasmic domain, 535IVVY538 motif, which is crucial for osteoclast differentiation. We demonstrated that mutational inactivation of RANK IVVY motif blocked osteoclast differentiation and significantly attenuated C/EBPα, but not PU.1, expression, indicating that RANK-IVVY-induced signaling is dispensable to PU.1 upregulation during osteoclastogenesis. However, C/EBPα or PU.1 overexpression failed to promote osteoclastogenesis in cells expressing mutated RANK IVVY motif. We noted that RANK-IVVY-motif inactivation significantly repressed osteoclast genes as compared with a vector control, suggesting that IVVY motif might also negatively regulate osteoclast inhibitors during osteoclastogenesis. Consistently, IVVY-motif inactivation triggered upregulation of RBP-J, a potent osteoclast inhibitor, during osteoclastogenesis. Notably, C/EBPα or PU.1 overexpression in cells expressing mutated RANK IVVY motif failed to control the deregulated RBP-J expression, resulting in repression of osteoclast genes. Accordingly, RBP-J silencing in the mutant cells rescued osteoclastogenesis with C/EBPα or PU.1 overexpression. In conclusion, we revealed that while PU.1 and C/EBPα are critical for osteoclastogenesis, they respond differently to RANKL-induced activation of RANK IVVY motif.

Indexed as

Amino Acid MotifsAnimalsCCAAT-Enhancer-Binding Protein-alphaCell DifferentiationMiceMice, Inbred C57BLOsteoclastsOsteogenesisProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Receptor Activator of Nuclear Factor-kappa BSignal TransductionTrans-ActivatorsCCAAT-Enhancer-Binding Protein-alphaProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Receptor Activator of Nuclear Factor-kappa BTrans-ActivatorsC/EBPαDifferentiationIVVY motifOsteoclastPU.1RANKRBP-J

Identifiers

PMID29032174
PMCPMC6240464
OpenAlexW2763743599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.